C57BL/6JCya-Cebpaem1flox/Cya
Common Name
Cebpa-flox
Product ID
S-CKO-01692
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-12606-Cebpa-B6J-VA
Status
When using this mouse strain in a publication, please cite “Cebpa-flox Mouse (Catalog S-CKO-01692) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Cebpa-flox
Strain ID
CKOCMP-12606-Cebpa-B6J-VA
Gene Name
Product ID
S-CKO-01692
Gene Alias
Cebp, CBF-A, C/ebpalpha
Background
C57BL/6JCya
Gene Full Name
CCAAT/enhancer binding protein (C/EBP), alpha
Modification
Conditional knockout
NCBI ID
Phenotype
Chromosome
Chr 7 (Mouse)
Application
--
Datasheet
Strain Description
Ensembl Transcript ID
ENSMUST00000042985
NCBI Transcript ID
NM_007678
Target Region
Exon 1
Size of Effective Region
~4.8 kb
Overview of Gene Research
Cebpa, also known as CCAAT enhancer binding protein α, is a transcription factor that plays a crucial role in cell differentiation, particularly in the myeloid lineage [2,3,5]. It is involved in regulating genes related to cell growth, apoptosis, and the immune response. Mutations in Cebpa are significant in acute myeloid leukemia (AML) research [1,2,3,4,5,6].
In AML, biallelic Cebpa mutations are associated with favorable outcomes, and in-frame mutations in the basic leucine zipper domain (CEBPAbZIP-inf) confer a survival benefit. In 2958 AML patients on Children's Oncology Group trials, CEBPA-bZip mutations were found in 5.4% of patients, with 82.5% having a second Cebpa mutation (CEBPA-dm). Patients with CEBPA-dm and CEBPA-bZip had better event-free survival (EFS) and overall survival (OS) compared to those with CEBPA-wild-type (CEBPA-WT) [1]. In another study of 4708 adults with AML, CEBPAbi and CEBPAsmbZIP were associated with significantly improved OS and EFS, while CEBPAsmTAD was not [3]. Also, in a Japanese AML multi-center collaborative program of 1028 patients, Cebpa mutations in the bZIP domain were strongly associated with a favorable prognosis, including higher complete remission rates, better OS, and lower relapse risk [5].
In conclusion, Cebpa is essential for myeloid cell differentiation and its mutations are of great significance in AML. Studies on Cebpa-mutated AML patients, especially those focusing on different types of Cebpa mutations, have provided insights into the prognostic impact of these mutations, which can potentially inform treatment strategies for AML patients.
References：
1. Tarlock, Katherine, Lamble, Adam J, Wang, Yi-Cheng, Alonzo, Todd A, Meshinchi, Soheil. . CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. In Blood, 138, 1137-1147. doi:10.1182/blood.2020009652. https://pubmed.ncbi.nlm.nih.gov/33951732/
2. Tien, Feng-Ming, Hou, Hsin-An. 2024. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. In International journal of hematology, 120, 541-547. doi:10.1007/s12185-024-03773-5. https://pubmed.ncbi.nlm.nih.gov/38671183/
3. Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Schetelig, Johannes, Thiede, Christian. . CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. In Blood, 139, 87-103. doi:10.1182/blood.2020009680. https://pubmed.ncbi.nlm.nih.gov/34320176/
4. Georgi, Julia-Annabell, Stasik, Sebastian, Kramer, Michael, Gale, Rosemary, Thiede, Christian. 2024. Prognostic impact of CEBPA mutational subgroups in adult AML. In Leukemia, 38, 281-290. doi:10.1038/s41375-024-02140-x. https://pubmed.ncbi.nlm.nih.gov/38228680/
5. Wakita, Satoshi, Sakaguchi, Masahiro, Oh, Iekuni, Inokuchi, Koiti, Yamaguchi, Hiroki. . Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. In Blood advances, 6, 238-247. doi:10.1182/bloodadvances.2021004292. https://pubmed.ncbi.nlm.nih.gov/34448807/
6. Yuan, Ji, He, Rong, Alkhateeb, Hassan B. 2023. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations. In Current hematologic malignancy reports, 18, 121-129. doi:10.1007/s11899-023-00699-3. https://pubmed.ncbi.nlm.nih.gov/37261703/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
